https://www.selleckchem.com/products/azd6738.html
05). After treatment, CD3 CD8 T-cell percentage of MT group was significantly higher than that of control group (p=0.01), while CD3 CD4 T-cell percentage of MT group was significantly lower than that of control group (p0.01). Thus, the CD4 /CD8 ratio of MT group was significantly lower than that of control group (p=0.03). In the subgroup of DLBCL patients treated with EPOCH/R-EPOCH, significant differences were also found in post-treatment CD3 CD8 T-cell percentage (p0.01), CD3 CD4 T-cell percentage (p=0.02) and CD4 /CD8 ratio (